CBS and Alzheimer disease: The latter most notably included [18F]FDG PET in virtually all patients, which has been demonstrated to be of high diagnostic value in parkinsonian syndromes and allows accurate distinction not only between AD-CBS and Aβ-negative CBS but also between pathologically verified PSP and CBD (15–17).